United Therapeutics Corporation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
United Therapeutics Corporation (UTHR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $19.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-25
- United Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $19.40M, a 14.12% increase from fiscal 2024.
- United Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $17.00M, a 335.90% increase from fiscal 2023.
- United Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $3.90M, a 57.61% decline from fiscal 2022.
- United Therapeutics Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $9.20M, a 22.03% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $19.40M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $17.00M 10-K · filed 2026-02-25 | $16.50M 10-K · filed 2025-02-26 |
| 2023-12-31 | $3.90M 10-K · filed 2026-02-25 | $3.50M 10-K · filed 2024-02-21 |
| 2022-12-31 | $9.20M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $11.80M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $11.50M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $6.30M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $2.10M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $1.80M 10-K · filed 2020-02-26 | |
| 2016-12-31 | -$11.40M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $29.30M 10-K · filed 2018-02-21 | $29.28M 10-K · filed 2016-02-25 |
| 2014-12-31 | $13.00M 10-K · filed 2017-02-22 | |
| 2013-12-31 | $22.81M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $2.61M 10-K · filed 2015-02-24 | |
| 2011-12-31 | -$2.61M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $7.34M 10-K · filed 2013-02-26 | |
| 2009-12-31 | $4.82M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |